Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours
โ Scribed by Winfried Brenner; Reinhard E. Friedrich; Karim A. Gawad; Christian Hagel; Andreas von Deimling; Maike de Wit; Ralph Buchert; Malte Clausen; Victor F. Mautner
- Publisher
- Springer
- Year
- 2006
- Tongue
- English
- Weight
- 109 KB
- Volume
- 33
- Category
- Article
- ISSN
- 0340-6997
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Neurofibromatosis type 1 (NF1) patients have 10% of lifetime risk for developing malignant peripheral nerve sheath tumors (MPNST), one of the most aggressive cancers. We examined the spectrum of constitutional NF1 mutations among 24 NF1 patients with MPNST. We found mutations in 18 patients: four me
Neurofibromatosis type-1 (NF1) is associated with the growth of benign and malignant tumors. Approximately 15% of NF1 patients develop malignant peripheral nerve sheath tumors (MPNSTs), underlining the need to identify specific diagnostic/prognostic biomarkers associated with MPNST development. The